linjc16/ctgov huggingface dataset:
Biomarkers of Chronic Obstructive Pulmonary Disease

Study Overview
=================
Brief Summary
-----------------
There are few studies about immunological explorations in COPD. Because of the complications of lung biopsies, analyses are generally made on blood samples instead of lung tissue. No study tried to classify COPD vs Asthma vs ACOS. The investigators wondered if there were differences in biomarkers between these groups. The investigators decided to open a pilot-study among COPD patients followed in Amiens-University Hospital. Each patient will be examined and a blood-test will be performed.

Official Title
-----------------
Specific Biomarker Identification of Different Subgroups of Chronic Obstructive Pulmonary Disease

Conditions
-----------------
COPD, Asthma-COPD Overlap Syndrome, Asthma

Intervention / Treatment
-----------------
* Other: Physical examinations
* Diagnostic Test: blood test


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: BPCO patients ACOS patients asthmatic patient without BPCO Exclusion Criteria: infection exacerbation immunosuppressive treatment immunosuppressive disease

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| frequent exacerbation patients<br> | Other: Physical examinations<br>* BPCO physical examinations<br>Diagnostic Test: blood test<br>* blood test in order to study immunologic markers<br>|
| non frequent exacerbation patients<br> | Other: Physical examinations<br>* BPCO physical examinations<br>Diagnostic Test: blood test<br>* blood test in order to study immunologic markers<br>|
| Asthma-and-COPD overlap syndrome<br> | Other: Physical examinations<br>* BPCO physical examinations<br>Diagnostic Test: blood test<br>* blood test in order to study immunologic markers<br>|
| Asthmatic patients (without COPD)<br> | Other: Physical examinations<br>* BPCO physical examinations<br>Diagnostic Test: blood test<br>* blood test in order to study immunologic markers<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| identification specific blood immunologic marker for COPD | COPD biomarkers are blood immunologic markers | one hour | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Complete blood count (CBC) Variation between COPD and asthmatic patients |  | one hour | 
| c-reactive protein concentration variation between COPD and asthmatic patients |  | one hour | 
| Plasma protein electrophoresis profile Variation between COPD and asthmatic patients |  | one hour | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
COPD, Asthma-COPD Overlap Syndrome, Asthma
Low Intensity Extracorporeal Shockwave Therapy for Patients With Erectile Dysfunction

Study Overview
=================
Brief Summary
-----------------
This is a prospective, pilot study for assessing the safety and efficacy of the treatments performed with Renova (LI-ESWT) on symptomatic ED patients.

Official Title
-----------------
A Prospective Multicenter Pilot Study to Assess the Safety and Efficacy of Low Intensity Extracorporeal Shockwave Therapy (LI-ESWT) by 'Renova' in Patients With Erectile Dysfunction

Conditions
-----------------
Vasculogenic Erectile Dysfunction

Intervention / Treatment
-----------------
* Device: Low intensity linear focused shockwave device ('Renova')


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Good general health Vasculogenic ED for at least 6 months International Index of Erectile Function 6 (IIEF-EF) between 11 to 25 Positive response to PDE5-I (able to penetrate on demand, Responders) Negative response to PDE5-I (unable to penetrate on demand even with maximum PDE5-I dosage,Non-responders) Stable heterosexual relationship for more than 3 months Exclusion Criteria: Psychogenic ED Neurological pathology Hormonal pathology Past radical prostatectomy Recovering from cancer during last 5 years Any unstable medical, psychiatric, spinal cord injury and penile anatomical - abnormalities Clinically significant chronic hematological disease Anti-androgens, oral or injectable androgens Radiotherapy in pelvic region

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Shockwaves<br>Low intensity linear focused shockwave device ('Renova') | Device: Low intensity linear focused shockwave device ('Renova')<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change from baseline in the IIEF-EF (International Index of Erectile Function- Erectile Function Domain) score at 1, 3 and 6 months post treatment |  | 1, 3 and 6 months post treatment | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change from baseline in the SEP (Sexual Encounter Profile) Questions 2 and 3 at 1, 3 and 6 months post treatment |  | 1, 3 and 6 months post treatment | 
| Responses to the GAQ (Global Assessment questions) Questions 1 and 2 at 1, 3 and 6 months post treatment |  | 1, 3 and 6 months post treatment | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Low Intensity Shockwave, Extracorporeal shockwave therapy, Erectile dysfunction
The Effect of Bevacizumab on Corneal Neovascularization

Study Overview
=================
Brief Summary
-----------------
Eight patients with corneal neovascularization were treated with subconjunctival injection of 1.25 mg bevacizumab and had a follow-up of at least 2 months. All patients had persistent corneal neovascularization for at least 6 months unresponsive to other treatments. Patients were monitored by ophthalmic exam and anterior segment photography.

Detailed Description
-----------------
To evaluate the effect of repeated subconjunctival bevacizumab (Avastin®, Roche, Rio de Janeiro, Brazil) on inflammatory corneal neovascularization. Eight patients with corneal neovascularization were treated with subconjunctival injection of 1.25 mg bevacizumab and had a follow-up of at least 2 months. All patients had persistent corneal neovascularization for at least 6 months unresponsive to other treatments. Patients were monitored by ophthalmic exam and anterior segment photography.

Official Title
-----------------
The Effect of Bevacizumab on Corneal Neovascularization

Conditions
-----------------
Corneal Neovascularization

Intervention / Treatment
-----------------
* Drug: Bevacizumab


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Corneal Neovascularization Stable lesion Exclusion Criteria: Diabetes Autoimmune diseases

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: 1<br>A single intraoperative subconjunctival application of bevacizumab and 2 months follow-up | Drug: Bevacizumab<br>* subconjunctival injection of 1.25 mg bevacizumab and had a follow-up of at least 2 months<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The Effect of Bevacizumab on Corneal Neovascularization | Eight patients with corneal neovascularization were treated with subconjunctival injection of 1.25 mg bevacizumab and had a follow-up of at least 2 months. All patients had persistent corneal neovascularization for at least 6 months unresponsive to other treatments. Patients were monitored by ophthalmic exam and anterior segment photography | Compare the results | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
bevacizumab, cornea, neovascularization
Electrical Impedance Tomography for Quantification of Pulmonary Edema in Acute Respiratory Distress Syndrome Patients

Study Overview
=================
Brief Summary
-----------------
Evaluation of pulmonary edema is a key factor in monitoring and guidance of therapy in acute respiratory distress syndrome (ARDS) patients. To date, methods available at the bedside for estimating the physiologic correlate of pulmonary edema, extravascular lung water(EVLW), often are unreliable or require invasive measurements. The purpose of the this study is to develop a novel approach to reliably assess extravascular lung water by electrical impedance tomography(EIT).

Conditions
-----------------
Acute Respiratory Distress Syndrome

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients will be included in this study if the following criteria have been met: Males and females > 18 years old and <85 years old (non-pregnant, non-lactating females). Patients fulfilled the Berlin diagnostic criteria of ARDS Signed written informed consent has been obtained Patients had monitoring system Pulse-Induced Contour Cardiac Output (PiCCO) Exclusion Criteria: Females who are pregnant or lactating. Patients with contraindication of EIT(Skin abrasions or wounds in the chest area.Patients with pacemakers or paced EKG rhythms.Thoracic deformity. Severe subcutaneous emphysema) Patients <18 years old or > 85 years old Patients Without monitoring system Pulse-Induced Contour Cardiac Output (PiCCO) Patients with Cardiac function of grade 4 or patients with acute myocardial infarction or acute coronary syndrome

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 85 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Comparison between a novel EIT-based method to estimate pulmonary edema (lung water ratio-EIT ) with a conventional measurement for EVLW using trans-cardiopulmonary thermodilution technique |  | once the patient was consented and enrolled |
Add-on to Cognitive, Event-Related Potentials (ERP) and Electroencephalogram (EEG) Asymmetry in Affective Disorders

Study Overview
=================
Brief Summary
-----------------
Depressed patients unremitted after monotherapy with citalopram or bupropion will remit following six weeks treatment with the combination of citalopram and bupropion.

Detailed Description
-----------------
Participants in another study who did not remit during 12 weeks treatment with citalopram (to 40 mg/d) or bupropion (to 450 mg/d) will have citalopram (to 40 mg/d) or bupropion (to 450 mg/d) added for six weeks.

Official Title
-----------------
Add-on to Cognitive, ERP and EEG Asymmetry in Affective Disorders (#6559R) [Formerly #5723]

Conditions
-----------------
Depressive Illness

Intervention / Treatment
-----------------
* Drug: bupropion
* Drug: citalopram


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: non-remission in Protocol #6559R age 18-66 signs informed consent physically healthy Exclusion Criteria: bipolar disorder history of psychosis history of anorexia nervosa or bulimia history of seizure disorder, significant brain trauma or other medical reason to suspect increased seizure risk

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 66 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Interventional Model Description: treatment in this study was determined by treatment received in prior study; i.e., those who had received escitalopram then receive escitalopram + bupropion; those initially taking bupropion then receive escitalopram + bupropion
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: bupropion added to citalopram<br>patients who did not remit with citalopram will continue at the same dose and have bupropion added | Drug: bupropion<br>* FDA approved drug for treating depression<br>* Other names: Wellbutrin;Drug: citalopram<br>* FDA approved treatment for depression<br>* Other names: Celexa;|
| Active Comparator: citalopram added to bupropion<br>Patients who did not remit with bupropion will have bupropion continued at the same dose and citalopram will be added | Drug: bupropion<br>* FDA approved drug for treating depression<br>* Other names: Wellbutrin;Drug: citalopram<br>* FDA approved treatment for depression<br>* Other names: Celexa;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Hamilton Rating Scale | Decrease in score for Hamilton Rating Scale for Depression, 17-item version | weeks 6 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
depression, citalopram, bupropion, combination therapy
Platelet Activation by a Collagen Analogue in Hemorrhagic Situations

Study Overview
=================
Brief Summary
-----------------
Dijon University Hospital and the Dijon-based NVH Medicinal Company have developed a recombinant mini-collagen NVH020B with platelet and Willebrand factor binding activity. Its small size and granular, non-fibrillar presentation make it suitable for use as an injectable hemostat in patients with a hemorrhage or other emergency under antiplatelet therapy.

Official Title
-----------------
Platelet Activation by a Collagen Analogue in Hemorrhagic Situations

Conditions
-----------------
Collagen Analog, Platelet Activation, Hemorrhage

Intervention / Treatment
-----------------
* Biological: Blood sampling


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: - person who has given their non-opposition to inclusion adult Healthy volunteers or controls (patients seen in consultation, without history of hemmorhage, etc.). or patients with acute bleeding: polytraumatized, or hemorrhage or intracerebral haemorrhage, or bleeding complications at the end surgery (in particular cardiac surgery with ECMO) or patients with antiplatelet therapy or patients with thrombocytopenia/thrombopathy Exclusion Criteria: protected adults (curatorship, guardianship) person deprived of their liberty by judicial or administrative decision pregnant, parturient or breastfeeding woman person unable to express their non-opposition platelet transfusion on initial management

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| controls<br>persons free of hemorrhage or haemostasis disorder | Biological: Blood sampling<br>* Blood sampling<br>|
| Haemorrhagic<br>Acute hemorrhagic patient | Biological: Blood sampling<br>* Blood sampling<br>|
| ECMO<br>ECMO surgery patient with hemorrhagic complication | Biological: Blood sampling<br>* Blood sampling<br>|
| polytrauma<br> | Biological: Blood sampling<br>* Blood sampling<br>|
| Platelet disorder<br>Patient with an identified platelet disorder or treated with antiplatelet agents | Biological: Blood sampling<br>* Blood sampling<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The expression of P-selectin and activated GPIIb/IIIa (PAC1) at the surface of platelets in flow cytometry in response to NVH020B. | These 2 markers are absent on the surface of resting platelets. The expression of these 2 markers will make it possible to evaluate the role of the mini-collagen as an activator. | Through study completion, an average of 1 year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Platelet aggregation rate in response to NVH020B |  | Through study completion, an average of 1 year |
Stapled vs Hand Sewn Anastomosis in Roux en Y Gastric Bypass for Morbid Obesity: Randomized Clinical Trial

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to compare postoperative complications between hand sewn and stapled anastomosis after performing Roux en Y-Gastric Bypass as a treatment for morbid obesity.

Official Title
-----------------
Stapled vs Hand Sewn Anastomosis in Roux en Y Gastric Bypass for Morbid Obesity: Randomized Clinical Trial

Conditions
-----------------
Morbid Obesity

Intervention / Treatment
-----------------
* Procedure: Roux en Y Gastric Bypass


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients over 18 years absence of previous bariatric surgery Exclusion Criteria: less than 18 years old coagulation disorders or liver cirrhosis

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: hand sewn anastomosis<br>Patients with hand sewn anastomosis during Roux en Y Gastric bypass performing | Procedure: Roux en Y Gastric Bypass<br> <br> |
| Active Comparator: stapled anastomosis<br>Patients with stapled anastomosis during Roux en Y Gastric Bypass performing | Procedure: Roux en Y Gastric Bypass<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| postoperative complications | To compare postoperative complications after bariatric surgery between stapled anastomosis and hand sewn anastomosis | within the first month after surgery | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| hospital stay |  | within the first month after surgery | 
| % of excess weight lost |  | five years after surgery | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Postoperative complications, Hand sewn anastomosis, Stapled anastomosis, Roux en Y Gastric Bypass
Task-Oriented Aerobic Exercise Training in Chronic Stroke Patients

Study Overview
=================
Brief Summary
-----------------
The study is designed to investigate (1) the effects of task-oriented aerobic exercise training on cardiorespiratory fitness, cerebral blood flow, oxygenation, functional performance, and physical activity in patients with chronic stroke. (2) the association between outcomes

Official Title
-----------------
Effects of Task-Oriented Aerobic Exercise Training on Cardiorespiratory Fitness and Cerebral Blood Flow in Chronic Stroke Patients

Conditions
-----------------
Cerebrovascular Accident

Intervention / Treatment
-----------------
* Other: Exercise training


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: poststroke duration > 6 months MMSE > 22 Exclusion Criteria: severe cardiovascular disease depression dementia other disease affect the testing of the study

Ages Eligible for Study
-----------------
Minimum Age: 30 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: Exercise<br>Exercise | Other: Exercise training<br>* aerobic exercise training<br>* Other names: Exercise;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| symptom-limited exercise test |  | 12 wks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| transcranial Doppler measurement |  | 12 wks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Physical fitness, Cerebral circulation, Walking
Buprenorphine Maintenance for Opioid Addicts - 2

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to evaluate varying doses of buprenorphine for opioid dependence and cocaine abuse.

Official Title
-----------------
Buprenorphine Maintenance for Opioid Addicts

Conditions
-----------------
Opioid-Related Disorders

Intervention / Treatment
-----------------
* Drug: Buprenorphine


Participation Criteria
=================
Eligibility Criteria
-----------------
Please contact site for information.
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Buprenorphine|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Drug use |  |  | 
| Withdrawal symptoms |  |  | 
| Psychological symptoms |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Opioid-Related Disorders